Plasma nociceptin levels are reduced in migraine without aura

Cephalalgia

Volumn 25, Issue 4, 2005, Pages 261-266

  Ertsey, Csaba ^a   Hantos, M ^b   Bozsik, G ^a   Tekes, K ^c  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Human; Migraine; Nociceptin; OP 4 receptor; Trigeminovascular system

Indexed keywords

NOCICEPTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DURA MATER; FEMALE; HEADACHE; HUMAN; MALE; MIGRAINE WITHOUT AURA; PAIN; PROTEIN DETERMINATION; PROTEIN FUNCTION; TRIGEMINAL NUCLEUS; VASODILATATION;

ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIGRAINE WITHOUT AURA; OPIOID PEPTIDES; RISK ASSESSMENT; RISK FACTORS; STATISTICS;

EID: 15944403961     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00849.x     Document Type: Article

References (44)

1. Sanchez del Rio M, Moskowitz MA. The trigeminal system. In: Olesen, J, Tfelt-Hansen, P, Welch, KMA, eds. The Headaches. Philadelphia: Lippincott. Williams & Wilkins 2000, 141-9.
2. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23:193-6.
3. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990; 16:69-75.
4. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33:48-56.
5. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat 1997; 190:367-75.
6. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 1991; 31:365-71.
7. Weiller C, May A, Limmroth V, Juptner M, Kaube H et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1:658-60.
8. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache 1987; 27:416-20.
9. Knight YE, Goadsby PJ. Brainstem stimulation inhibits trigeminal neurons in the cat. Cephalalgia 1999; 19:315.
10. Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience 2001; 106:793-800.
11. Hamon M. The new approach to opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 1998, 358: SA5., 3.
12. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, et al.a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 1995; 270:792-4.
13. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995; 377:532-5.
14. Moran TD, Abdulla FA, Smith PA. Cellular neurophysiological actions of nociceptin/orphanin FQ. Peptides 2000; 21:969-76.
15. Neal CR Jr, Mansour A, Reinscheid R, Nothacker HP, Civelli O et al. Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with 125, I-[(14) Tyr]-orphanin FQ binding. J Comp Neurol 1999, 412 (4), 563-605.
16. Bridge KE, Wainwright A, Reilly K, Oliver KR. Autoradiographic localization of 125, i[Tyr (14)] nociceptin/orphanin FQ binding sites in macaque primate CNS. Neuroscience 2003, 118 (2), 513-23.
17. Peluso J, LaForge KS, Matthes HW, Kreek MJ, Kieffer BL, Gaveriaux-Ruff C. Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. J Neuroimmunol 1998; 81:184-92.
18. Mollereau C, Mouledous L. Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 2000; 21:907-17.
19. Giuliani S, Lecci A, Maggi CA. Nociceptin and neurotransmitter release in the periphery. Peptides 2000; 21:977-84.
20. Ko MC, Naughton NN, Traynor JR, Song MS, Woods JH et al. Orphanin FQ inhibits capsaicin-induced thermal nociception in monkeys by activation of peripheral ORL1 receptors. Br J Pharmacol 2002; 135:943-50.
21. Darland T, Heinricher MM, Grandy DK, Orphanin FQ. nociceptin. a role in pain and analgesia, but so much more. Trends Neurosci 1998; 21:215-21.
22. Grisel JE, Mogil JS. Effects of supraspinal orphanin FQ/nociceptin. Peptides 2000; 21:1037-45.
23. Ruscheweyh R, Sandkuhler J. Bidirectional actions of nociceptin/orphanin FQ on A delta-fibre-evoked responses in rat superficial spinal dorsal horn in vitro. Neuroscience 2001; 107:275-81.
24. Hou M, Uddman R, Tajti J, Edvinsson L. Nociceptin immunoreactivity and receptor mRNA in the human trigeminal ganglion. Brain Res 2003; 964:179-86.
25. Hantos MB, Szalay F, Lakatos PL, Hegedus D, Firneisz G et al. Elevated plasma nociceptin level in patients with Wilson disease. Brain Res Bull 2002; 58:311-3.
26. Brooks H, Elton CD, Smart D, Rowbotham DJ, McKnight AT, Lambert DG. Identification of nociceptin in human cerebrospinal fluid: comparison of levels in pain and non-pain states. Pain 1998; 78:71-3.
27. Anderberg UM, Liu Z, Berglund L, Nyberg F. Plasma levels on nociceptin in female fibromyalgia syndrome patients. Z Rheumatol 1998; 57 Suppl 2:77-80.
28. Ertsey C, Hantos M, Bozsik G, Tekes K. Circulating nociceptin levels during the cluster headache period. Cephalalgia 2004; 24:280-3.
29. Ko MH, Kim YH, Woo RS, Kim KW. Quantitative analysis of nociceptin in blood of patients with acute and chronic pain. Neuroreport 2002; 13:1631-3.
30. Mork H, Hommel K, Uddman R, Edvinsson L, Jensen R. Does nociceptin play a role in pain disorders in man? Peptides 2002; 23:1581-7.
31. Kumar N, Smart D, Mason S, McKnight AT, Rowbotham DJ, Lambert DG. Neither nociceptin nor its receptor are present in human synovial fluid or tissue. Br J Anaesth 1999; 83:470-1.
32. Helyes Z, Nemeth J, Pinter E, Szolcsanyi J. Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. Br J Pharmacol 1997; 121:613-5.
33. Habler H, Timmermann L, Stegmann J, Janig W. Effects of nociceptin and nocistatin on antidromic vasodilatation in hairless skin of the rat hindlimb in vivo. Br J Pharmacol 1999; 127:1719-27.
34. Bartsch T, Akerman S, Goadsby PJ. The ORL-1 (NOP (1) receptor ligand nociceptin/orphanin FQ (N/OFQ) inhibits neurogenic dural vasodilatation in the rat. Neuropharmacology 2002; 43:991-8.
35. Maggi CA. The pharmacology of the efferent function of sensory nerves. J Auton Pharmacol 1991; 11:173-208.
36. Williamson DJ, Shepheard SL, Cook DA, Hargreaves RJ, Hill RG, Cumberbatch MJ. Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurons in anaesthetized rats. Br J Pharmacol 2001; 133:807-14.
37. Reinscheid RK, Nothacker H, Civelli O. The orphanin FQ/nociceptin gene: structure, tissue distribution of expression and functional implications obtained from knockout mice. Peptides 2000; 21:901-6.
38. Ferrari MD, Bach FW. Biochemistry of systemic and jugular venous blood. In: Olesen, J, Tfelt-Hansen, P, Welch, KMA, eds. The Headaches. Philadelphia: Lippincott. Williams & Wilkins 2000, 255-60.
39. Leone M, Sacerdote P, D'Amico D, Panerai AE, Bussone G. Beta-endorphin concentrations in the peripheral blood mononuclear cells of migraine and tension-type headache patients. Cephalalgia 1992; 12:154-7.
40. Wang XM, Zhang KM, Long LO, Mokha SS. Orphanin FQ (nociceptin) modulates responses of trigeminal neurons evoked by excitatory amino acids and somatosensory stimuli, and blocks the substance P-induced facilitation of N-methyl-D-aspartate-evoked responses. Neuroscience 1999; 93:703-12.
41. Yang ZL, Zhang YQ, Wu GC. Effects of microinjection of OFQ into PAG on spinal dorsal horn WDR neurons in rats. Brain Res 2001; 888:167-71.
42. Morgan MM, Grisel JE, Robbins CS, Grandy DK. Antinociception mediated by the periaqueductal gray is attenuated by orphanin FQ. Neuroreport 1997; 8:3431-4.
43. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review), report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754-62.
44. Calo' G, Guerrini R, Bigoni R, Rizzi A, Marzola G et al. Characterization of [Nphe (1) ]nociceptin (1-13) NH (2), a new selective nociceptin receptor antagonist. Br J Pharmacol 2000; 129:1183-93.